Products
Next generation Epothilones
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies.
Epothilones are regarded as very promising product candidates for the treatment of cancer diseases. The novel next generation epothilones of R&D-Biopharmaceuticals are designed to allow for conjugation to polymers or biomolecules to overcome the severe ADRs of approved and epothilones.
More Products
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010